Edward Tenthoff
Stock Analyst at Piper Sandler
(3.17)
# 1,147
Out of 5,131 analysts
192
Total ratings
43.65%
Success rate
2.42%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintains: Overweight | $6 → $8 | $1.63 | +390.80% | 1 | Jan 9, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $70 → $100 | $65.93 | +51.68% | 13 | Dec 17, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $24.51 | +83.60% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $73.09 | +71.02% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $9.51 | +141.85% | 6 | Dec 8, 2025 | |
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $33.84 | +86.17% | 13 | Nov 21, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $1.54 | +289.61% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $370.91 | +31.84% | 15 | Oct 31, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $8.20 | +46.43% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $6.04 | +98.68% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $13.51 | +11.03% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $55.30 | +89.87% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $11.33 | +76.52% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.46 | +379.45% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $12.15 | +15.23% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $2.04 | -1.96% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $17.46 | +174.91% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $18.67 | +28.55% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $23.70 | +229.11% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $14.17 | +111.71% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.86 | +2,172.73% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.94 | +2,025.17% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.33 | +125.56% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.35 | +769.57% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $23.72 | -32.55% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.07 | +460.75% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.96 | +155.10% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $34.46 | +619.67% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.90 | +2,207.69% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $15.84 | +1,036.36% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.85 | +146.50% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $6.59 | +461.88% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $8.97 | +130,675,485.28% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $796.00 | -55.53% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.12 | +11,953.57% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $460.59 | -29.87% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.29 | +142.95% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $44.06 | -18.29% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.83 | +1,266.12% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.65 | +22,976.92% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.47 | +2,963,817.53% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $768.00 | - | 11 | Feb 13, 2017 |
Acrivon Therapeutics
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.63
Upside: +390.80%
Arrowhead Pharmaceuticals
Dec 17, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $65.93
Upside: +51.68%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $24.51
Upside: +83.60%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $73.09
Upside: +71.02%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $9.51
Upside: +141.85%
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $33.84
Upside: +86.17%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.54
Upside: +289.61%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $370.91
Upside: +31.84%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $8.20
Upside: +46.43%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $6.04
Upside: +98.68%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $13.51
Upside: +11.03%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $55.30
Upside: +89.87%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $11.33
Upside: +76.52%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.46
Upside: +379.45%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $12.15
Upside: +15.23%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $2.04
Upside: -1.96%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $17.46
Upside: +174.91%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $18.67
Upside: +28.55%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $23.70
Upside: +229.11%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $14.17
Upside: +111.71%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.86
Upside: +2,172.73%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.94
Upside: +2,025.17%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.33
Upside: +125.56%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.35
Upside: +769.57%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $23.72
Upside: -32.55%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.07
Upside: +460.75%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.96
Upside: +155.10%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $34.46
Upside: +619.67%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.90
Upside: +2,207.69%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $15.84
Upside: +1,036.36%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.85
Upside: +146.50%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $6.59
Upside: +461.88%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $8.97
Upside: +130,675,485.28%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $796.00
Upside: -55.53%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.12
Upside: +11,953.57%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $460.59
Upside: -29.87%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.29
Upside: +142.95%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $44.06
Upside: -18.29%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.83
Upside: +1,266.12%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.65
Upside: +22,976.92%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.47
Upside: +2,963,817.53%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $768.00
Upside: -